替勃龙治疗绝经后更年期综合征患者的有效性

Efficacy of Tibolone in the Treatment of Postmenopausal Syndrome

目的探讨绝经后更年期综合征患者应用替勃龙治疗的有效性。方法随机选取在濮阳油田总医院2021年2月至2023年2月接受治疗的绝经后更年期综合征患者87例,按照治疗药物的不同将所有患者分为对照组(n=43,坤泰胶囊治疗)及观察组(n=44,替勃龙治疗)。评估两组患者治疗效果、激素水平、免疫功能、生活质量及药物不良反应发生率。结果观察组患者绝经后更年期综合征症状评分低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者雌二醇水平增加、黄体生成素与血清卵泡激素水平下降,且观察组雌二醇水平高于对照组,黄体生成素与血清卵泡激素水平低于对照组,差异有统计学意义(P<0.05)。治疗后两组CD3^(+)、CD4^(+)与CD4^(+)/CD8^(+)指标高于治疗前,CD8^(+)指标低于治疗前,且观察组CD3^(+)、CD4^(+)与CD4^(+)/CD8^(+)指标高于对照组,CD8^(+)指标低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者生活质量评分均提高,且观察组患者生活质量评分高于对照组,差异有统计学意义(P<0.05)。观察组发生阴道出血、乳房胀痛、胃肠道不适、头晕的药物不良反应发生率为6.83%,对照组为11.83%,观察组药物不良反应发生率与对照组相比,差异无统计学意义(P>0.05)。结论替勃龙能有效减轻绝经后更年期综合征患者因激素失衡引起的不适症状,有助于增强免疫功能,且用药不良反应相对较少,帮助患者抵抗疾病,进而使得患者能够更好地应对日常生活。

Objective To explore the efficacy of tibolone in the treatment of postmenopausal syndrome.Methods A total of 87 patients with postmenopausal syndrome treated at Puyang Oilfield General Hospital from February 2021 to February 2023 were randomly selected.All patients were divided into a control group(n=43,treated with Kuntai Capsules)and an observation group(n=44,treated with tibolone)based on the different treatment drugs.The treatment effects,hormone levels,immune function,quality of life,and incidence of adverse drug reactions were evaluated in both groups.Results The symptom scores of postmenopausal syndrome in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).After treatment,the estradiol levels increased,and the levels of luteinizing hormone and serum follicle-stimulating hormone decreased in both groups.The estradiol levels in the observation group were higher than those in the control group,while the levels of luteinizing hormone and serum follicle-stimulating hormone were lower than those in the control group,with statistically significant differences(P<0.05).After treatment,the CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)indicators in both groups were higher those before treatment,and the CD8^(+)indicators were lower than before treatment.The CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)indicators in the observation group were higher than those in the control group,while the CD8^(+)indicators were lower than those in the control group,with statistically significant differences(P<0.05).After treatment,the quality of life scores in both groups improved,and the quality of life scores in the observation group were higher than those in the control group,with statistically significant differences(P<0.05).The incidence of adverse drug reactions such as vaginal bleeding,breast tenderness,gastrointestinal discomfort,and dizziness in the observation group was 6.83%,compared to 11.83%in the control group.There was no statistically significant difference in the incidence of adverse drug reactions between the observation group and the control group(P>0.05).Conclusion Tibolone can effectively alleviate the discomfort symptoms caused by hormonal imbalance in patients with postmenopausal syndrome,help enhance immune function,and has relatively fewer adverse drug reactions.It helps patients resist diseases and enables them to better cope with daily life.